Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania Health System, Philadelphia, PA, USA.
Immunotherapy. 2012 Oct;4(10):995-1009. doi: 10.2217/imt.12.100.
After decades of extensive research, epithelial ovarian cancer still remains a lethal disease. Multiple new studies have reported that the immune system plays a critical role in the growth and spread of ovarian carcinoma. This review summarizes the development of dendritic cell (DC) vaccinations specific for ovarian cancer. So far, DC-based vaccines have induced effective antitumor responses in animal models, but only limited results from human clinical trials are available. Although DC-based immunotherapy has proven to be clinically safe and efficient at inducing tumor-specific immune responses, its clear role in the therapy of ovarian cancer still needs to be clarified. The relatively disappointing low-response rates in early clinical trials point to the need for the development of more effective and personalized DC-based anticancer vaccines. This article reviews the basic mechanisms, limitations and future directions of DC-based anti-ovarian cancer vaccine development.
经过几十年的广泛研究，上皮性卵巢癌仍然是一种致命的疾病。多项新的研究报告指出，免疫系统在卵巢癌的生长和扩散中起着关键作用。这篇综述总结了针对卵巢癌的树突状细胞（DC）疫苗的发展。到目前为止，基于 DC 的疫苗在动物模型中已诱导出有效的抗肿瘤反应，但只有有限的人类临床试验结果可用。尽管基于 DC 的免疫疗法已被证明在诱导肿瘤特异性免疫反应方面具有临床安全性和有效性，但它在卵巢癌治疗中的明确作用仍需阐明。早期临床试验中相对令人失望的低反应率表明需要开发更有效和个性化的基于 DC 的抗癌疫苗。本文综述了基于 DC 的抗卵巢癌疫苗开发的基本机制、局限性和未来方向。
